CA
NZ
UK
AU
IND
US
Haemonetics (NYSE:HAE) shares closed at USD 119.47 on October 8, 2026, up 17.46%, which implies a prior close near USD 101.71, simple arithmetic on the two published figures. A recap attributed the move to an updated non-exclusive US supply agreement with CSL Plasma covering …
Kyverna Therapeutics (NASDAQ:KYTX) was indicated up 5.34% in the October 9, 2026 premarket session on the screener, on a listed price of USD 6.18 and premarket volume of only 100 shares. The screener tags the catalyst as news, yet a search found no company …
The FDA approved Tecentriq, known generically as atezolizumab, on October 8, 2026 for adjuvant treatment of stage III colon cancer with deficient mismatch repair, abbreviated dMMR. Adjuvant means given after surgery to reduce the chance of recurrence. The approval came one day before the …
Definium Therapeutics (NASDAQ:DFTX) was indicated up 5.24% in the October 9, 2026 premarket session on the screener, on a listed price of USD 34.18 and premarket volume of 2,978 shares. The screener lists no catalyst, and a search found no company announcement or filing …
Doximity (NYSE:DOCS) reported fiscal first-quarter revenue of USD 156.6 million, an increase of 7%, according to a secondary summary of the company release on October 8, 2026. Net income was USD 24.3 million, compared with USD 53.3 million a year earlier, a drop of …
Eikon Therapeutics (NASDAQ:EIKN) was indicated up 6.00% in the October 9, 2026 premarket session on the screener, on a listed price of USD 7.50 and premarket volume of only 100 shares. The screener lists no catalyst, and a search found no company announcement from …
Bayer said on October 8, 2026 that the FDA accepted its supplemental new drug application for Kerendia in non-diabetic chronic kidney disease. The application is based on the FIND-CKD trial. A supplemental application seeks to expand the approved use of a drug already on …
AngioDynamics (NASDAQ:ANGO) announced on October 8, 2026 that Eric Honroth will succeed retiring chief executive Jim Clemmer, who leaves the board on November 2. The announcement came with quarterly results in a company release and an 8-K filing. The topics file does not describe …
Pfizer (NYSE:PFE) said the FDA approved Tukysa, known generically as tucatinib, for first-line maintenance treatment in HER2-positive breast cancer. The supporting figure is progression-free survival of 24.9 months versus 16.3 months for the comparison group. Progression-free survival measures how long patients live without their …
argenx (NASDAQ:ARGX) said it is discontinuing a late-stage trial of efgartigimod in Sjogren's disease because the study did not show enough efficacy, according to a company announcement reported on October 8, 2026. The shares fell, but the file does not give the size of …
Please wait processing your request...